Silencing MAGE‐C1/CT7 resulted in a statistically significant increase in the percentage of myeloma cells in G0/G1 phase and significantly decreased the number of cells in the G2/M phase of the cell cycle.25 In addition, some studies have shown an association between the expression of CTAs and a phenotype of resistance to chemotherapy treatments.26 Here, MAGEC1 is linked to plasma cell myeloma.